Asensus Surgical — TransEnterix — Merger or Acquisition (September 2015)
24 slides from Asensus Surgical's merger presentation, Sep 21, 2015
Slide 1: A Compelling Acquisition to Accelerate our Strategy to Transform Robotic Surgery
A Compelling Acquisition to Accelerate our Strategy to Transform Robotic Surgery Sept 22, 2015 Exhibit 99.1
Slide 2: Speakers on Today's Call
Speakers on Today’s Call Todd M. Pope President & CEO Joe Slattery EVP & CFO
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation includes statements relating to TransEnterix’s acquisition of the TELELAP ALF-X surgical robotic system from SOFAR S.p.A. and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future
Slide 4: TransEnterix Vision
TransEnterix Vision Our vision is to improve clinical outcomes and patient care through the use of robotics in surgery. We seek to enhance and support surgeon capabilities while reducing the barriers to adoption with responsible economics and leveraging existing laparoscopic skills.
Slide 5: Creation of a Disruptive Surgical Robotics Company
Creation of a Disruptive Surgical Robotics Company Combination of SurgiBot and ALF-X allows TransEnterix to address a larger market opportunity with compelling patient, surgeon and hospital value Unique and complementary surgical robotics portfolio • Technologically innovative • Economically disrupt
Slide 6: Transaction Overview
Transaction Overview • Acquiring surgical robotics division of SOFAR, an Italian health care company • Total consideration of $99.8 million • Transaction closed Sept 21, • Integration expected to be completed within six months • $68.7 million upfront payment • $25.0 million cash • $43.7 million in s
Slide 7: Transaction Background
Transaction Background SOFAR developed ALF-X, a unique multi-port surgical robotics platform Gained regulatory clearance in EU and generated compelling data SOFAR sought a partner with: Focus on surgical robotics Ability to share in the success Shared vision
Slide 8: Shared Vision for Growth Dynamics
Shared Vision for Growth Dynamics Future growth of surgical robotics will be defined by disruptive innovation, both from a technological and economic perspective Growth Drivers: Build on success of laparoscopy while addressing limitations Innovative technology that addresses trade-offs Compelling ec
Slide 9: Build on the Success of Laparoscopy
Build on the Success of Laparoscopy Traditional laparoscopy remains the dominant form of minimally invasive surgery Over 6 million laparoscopic procedures across US and CE Mark countries* Surgeons are experienced with approach, technique and instrument motion *Data source: Millennium Research Group
Slide 10: Technology that Addresses Trade-offs: Limitations of Laparoscopy
Technology that Addresses Trade-offs Reliance on assistant to control camera Challenging ergonomics Imprecise instrument movement Difficulty suturing Torque at incision sites Limitations of traditional laparoscopy
Slide 11: Technology that Addresses Trade-offs: Limitations of Current Robotic Systems
Technology that Addresses Trade-offs No haptic feedback Disengagement with surgical field Increasing size of typical trocar incision Limits ability to reposition patient by docking to trocars Camera movement requires use of surgeon hands Limitations of current robotic systems
Slide 12: Compelling Economic Value to Hospitals
Compelling Economic Value to Hospitals Limitations of current robotic systems Hospitals are concerned about capital and procedure costs for robotics Lack of additional reimbursement Concern over adding procedure costs with robotics • Laparoscopy: majority of instruments reusable • Robotics: majority
Slide 13: ALF-X System: Builds on Success of Laparoscopy
ALF-X System: Builds on Success of Laparoscopy Multi-port system Laparoscopic motion Utilizes standard laparoscopic trocars 5mm instruments Force sensing for minimal torque
Slide 14: ALF-X System: Technology Addresses Trade-offs
ALF-X System: Technology Addresses Trade-offs Haptic feedback Open architecture • Open view of operating room • Open source ports allow both robotic and traditional lap instruments Standard size trocar incisions Ease of patient repositioning • No docking to trocar Enhanced vision • 3DHD controlled v
Slide 15: ALF-X System: Compelling Economic Value
ALF-X System: Compelling Economic Value Disruptive robotic per-procedure pricing model • Reusable instruments • Minimal disposables per case Broad instrument offering • instruments • Select wristed instruments Access to robotics with operational costs similar to many traditional laparoscopic procedu
Slide 16: Accelerates our Commercialization Timeline
Accelerates our Commercialization Timeline SALES STRATEGY SALES STRATEGY TIMING TIMING GEOGRAPHIC TARGETS GEOGRAPHIC TARGETS Existing CE Mark allows for near-term commercialization of ALF-X • Mix of direct sales and distributors • Build out of team will begin immediately • Sales beginning in Q1 2016
Slide 17: Complementary Portfolio
Complimentary Portfolio System Multi-port Single-port Initial Geographic Focus Europe and Middle East United States Regulatory Status CE Mark FDA 510k Under Review Key Technological Innovations Haptic Feedback Open Console Laparoscopic Motion Eye Tracking 3D Camera Control Tactile Feedback Patient-s
Slide 18: SurgiBot Update
SurgiBot Update REGULATORY COMMERCIAL • Additional information request received from FDA • Timing guidance maintained • Clearance expected – Q1 2016 • Appointed Paul Ziegler VP of Sales • Actively building sales and service teams Remain on track for expected Q2 2016 launch
Slide 19: Milestones
Milestones 2015 • Q3 - American College of Surgeons • Q4 - Appoint International Leadership 2016 • Q1 - ALF-X Sales Commence • Q1 - SurgiBot US Regulatory Clearance • Q1 - Complete Integration • Q2 - SurgiBot US Commercial Launch 2017 • ALF-X US Commercial Launch • Expansion into Additional Internat
Slide 20: Detailed Transaction Structure
Detailed Transaction Structure Total Consideration: $99.8M COMPONENTS: $43.7M in stock •15.5M shares,15.5% ownership •Lock-up released between first and second anniversary •Registration rights $25.0M cash up front $2.8M (€2.5M) payable Dec 31, $11.3M (€10.0M) payable earlier of ALF-X FDA clearance o
Slide 21: Compelling Financial Rationale
Compelling Financial Rationale Expands addressable market • Geographies • Customers • Procedures Accelerates and significantly increases revenue opportunity Shortens time to cash flow break even • Expected late 2018 • Reduced overall cash needs Leverages already-planned distribution and support inve
Slide 22: Summary
Summary Creates disruptive surgical robotics company Accelerates and significantly increases revenue opportunity Significantly expands market opportunity • Access to global markets SurgiBot and ALF-X both address our vision for growth • Mimic laparoscopic motions • Address limitations of laparoscopy
Slide 23: TransEnterix Vision
TransEnterix Vision Our vision is to improve clinical outcomes and patient care through the use of robotics in surgery. We seek to enhance and support surgeon capabilities while reducing the barriers to adoption with responsible economics and leveraging existing laparoscopic skills.
Slide 24: TransEnterix
Wransenterix
TransEnterix — Merger or Acquisition (September 2015) on 6ix